Liquidia Technologies Inc (LQDA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Liquidia Technologies Inc stock (LQDA) is currently trading at $36.61. Liquidia Technologies Inc PS ratio (Price-to-Sales) is 19.59. Analyst consensus price target for LQDA is $50.67. WallStSmart rates LQDA as Sell.
- LQDA PE ratio analysis and historical PE chart
- LQDA PS ratio (Price-to-Sales) history and trend
- LQDA intrinsic value — DCF, Graham Number, EPV models
- LQDA stock price prediction 2025 2026 2027 2028 2029 2030
- LQDA fair value vs current price
- LQDA insider transactions and insider buying
- Is LQDA undervalued or overvalued?
- Liquidia Technologies Inc financial analysis — revenue, earnings, cash flow
- LQDA Piotroski F-Score and Altman Z-Score
- LQDA analyst price target and Smart Rating
Liquidia Technologies Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Liquidia Technologies Inc (LQDA) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, revenue growth, institutional own.. Concerns around return on equity and price/sales. Mixed signals suggest waiting for clearer direction before acting.
Liquidia Technologies Inc (LQDA) Key Strengths (4)
Revenue surging 3055.00% year-over-year
71.07% of shares held by major funds and institutions
Strong operational efficiency: $22 kept per $100 revenue
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Liquidia Technologies Inc (LQDA) Areas to Watch (4)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Very expensive at 19.6x annual revenue
Very expensive at 71.7x book value
Supporting Valuation Data
Liquidia Technologies Inc (LQDA) Detailed Analysis Report
Overall Assessment
This company scores 36/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 4 register as strengths (avg 8.8/10) while 4 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Operating Margin. Profitability is solid with Operating Margin at 21.50%. Growth metrics are encouraging with Revenue Growth at 3055.00%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, Price/Sales. Some valuation metrics including Price/Sales (19.59), Price/Book (71.66) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -111.10%, Profit Margin at -43.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -111.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 3055.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
LQDA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
LQDA's Price-to-Sales ratio of 19.59x trades 25% below its historical average of 26.08x (0th percentile). The current valuation is 55% below its historical high of 43.39x set in Mar 2026, and 0% above its historical low of 19.59x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~39.0x as trailing revenue scaled faster than the stock price.
Compare LQDA with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Liquidia Technologies Inc (LQDA) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Liquidia Technologies Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 158M with 3055% growth year-over-year. The company is currently unprofitable, posting a -43.5% profit margin.
Key Findings
Revenue growing at 3055% YoY, reaching 158M. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
Generating 42M in free cash flow and 44M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -43.5% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Liquidia Technologies Inc maintain 3055%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Liquidia Technologies Inc.
Bottom Line
Liquidia Technologies Inc is a high-conviction growth story with revenue accelerating at 3055% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -43.5% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(84 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 4:27:23 PM
About Liquidia Technologies Inc(LQDA)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is headquartered in Morrisville, North Carolina.